Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients
Matthieu Monge, Irina Shahapuni, Roxana Oprisiu, Najeh El Esper, Philippe Morinière, Ziad Massy, Gabriel Choukroun and Albert Fournier*
Correspondence *Hôpital Sud, Department of Nephrology, 80054 Amiens, Cedex 1, France
Email fournier.albert@chu-amiens.fr
Since the latest K/DOQI guidelines were formulated, new data on drugs such as lanthanum carbonate and calcimimetics have become available. In light of this new information, Matthieu Monge and colleagues believe that current practice can be updated. In this Review, the authors outline their recommendations regarding drug selection, dosing regimens, and monitoring of hyperparathyroidism in dialysis patients.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidismNature Clinical Practice Nephrology Article Response (01 Apr 2007)
Achieving NKF-K/DOQI? bone metabolism and disease treatment goals with cinacalcet HClKidney International Trade News
See all 73 matches for Research